Title of article
Successful intravenous thrombolysis in acute ischemic stroke after reversal of dabigatran etexilate with idarucizumab at the end of therapeutic time window
Author/Authors
Vukorepa, Gorana Department of Neurology - University Hospital Dubrava - Zagreb, Croatia , Deveđija, Sabina Department of Neurology - University Hospital Dubrava - Zagreb, Croatia , Crnjaković, Miljenko Department of Neurology - University Hospital Dubrava - Zagreb, Croatia , Karakaš, Mirna Department of Neurology - University Hospital Dubrava - Zagreb, Croatia , Ćuk, Željka Department of Neurology - University Hospital Dubrava - Zagreb, Croatia
Pages
3
From page
90
To page
92
Abstract
Dabigatran is a direct oral anticoagulant that is widely used for stroke prevention in patients with atrial fibrillation. We report a case of an 80‑year‑old stroke patient on dabigatran for permanent atrial fibrillation, who presented with an initial National Institutes of Health Stroke Scale (NIHSS) of 8. Dabigatran was reversed with idarucizumab, and intravenous tissue-type plasminogen activator (IV-tPA) was administrated beginning 4 h and 28 min after the symptom onset. The patient was discharged with an NIHSS of 1. Our case is an additional proof of safety and efficiency of idarucizumab in the clinical setting of ischemic stroke before the administration of IV-tPA.
Keywords
idarucizumab thrombolysis , anticoagulants dabigatran , acute stroke therapy , Acute ischemic stroke
Journal title
Turkish Journal of Emergency Medicine
Serial Year
2020
Record number
2579395
Link To Document